×
Fintech Bolt progresses its turnaround by landing Klarna as a partner | TechCrunch

Fintech Bolt progresses its turnaround by landing Klarna as a partner | TechCrunch

Klarna and Bolt announced a partnership Monday, which will see Klarna’s payment options integrated into Bolt’s checkout operating system.

This deal means Klarna will show up as a buy now, pay later choice on Bolt devices. Merchants using Bolt can offer Klarna’s Pay in 4 or monthly financing options to shoppers in physical stores, and shoppers can choose that option with a single click. The integration is set to go live later this year, first in the U.S. and then in other markets around the world. 

In a statement given to TechCrunch, Ryan Breslow, co-founder and CEO of Bolt, told us that the partnership was “so much bigger than two companies working together.” 

“It’s a clear sign that commerce is moving in an entirely new direction,” he said, adding that this will not be another buy now, pay later option but, rather, “an entirely new model that offers best-in-class, flexible customer experience with no new contracts or technical lift required.” 

Klarna, which has been waiting in the wings to go public since the spring, describes the partnership as a means to drive long-term loyalty for itself and merchants.

“By embedding Klarna into thousands of Bolt merchants, we’re scaling our U.S. footprint and making Klarna available everywhere consumers shop,” a Klarna spokesperson said.  

This latest partnership is a big deal for Bolt for other reasons. The fintech has struggled in recent years with legal challenges and upset investors. In March, Bolt founder Breslow returned as CEO after having stepped down in early 2022.

In August, Bolt was reportedly attempting to raise $450 million at a potential $14 billion valuation, but it was an oddball deal with strange terms, including a “cramdown” threat to existing shareholders. There have been no updates on that apparent deal, but Bloomberg reported earlier this month that Breslow was once again looking to raise. This time, he’s looking for at least $600 million, half of which would go to Bolt, while the other half would go to his other startup, Love. Breslow has said that Bolt has at least three years of runway left. 

Earlier this month, Bolt also announced a partnership with Palantir to launch an AI-powered personalized checkout that remembers the shopping habits of consumers. It wants to expand this checkout across its merchants and within Bolt’s new SuperApp, a “one-click crypto and everyday payments” app, as he described to us in an April interview. 

Adding two big names as partners, Klarna and Palantir, is the kind of step that could help clean up Bolt’s reputation as it seeks to raise again.

Source link
#Fintech #Bolt #progresses #turnaround #landing #Klarna #partner #TechCrunch

confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo">OPPO Confirms Find X9s and Find X9 Ultra India Launch Date

OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.

OPPO Find X9 Ultra and X9S: Specs

OPPO Confirms Find X9s and Find X9 Ultra India Launch Date
	
OPPO has officially confirmed that the Find X9S and Find X9 Ultra will launch in India on May 21. The new flagship smartphones are designed for users who prioritize photography and video creation, featuring upgraded Hasselblad camera setups. Alongside the camera upgrades, both smartphones also include large silicon-carbon batteries and dedicated cooling systems for stable performance.



OPPO Find X9 Ultra and X9S: Specs







OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.



The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.



The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.



Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.



India Launch Date and Expected Availability



OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo

OPPO has designed the Find X9S with a slim 7.99mm body while still offering premium camera and video capabilities. The device includes three 50MP cameras tuned with Hasselblad technology for consistent imaging results. It also supports Dolby Vision recording and AI features to enhance photos, videos, and everyday usability.

The Hasselblad Master Camera System is a key highlight of the Find X9 series. The purpose of the system is to ensure that the photos produced have balanced colors, good detail, and a consistent photography experience across all the camera sensors on the phone. Another technology OPPO uses to make their images even better is the LUMO Image Engine, which provides high dynamic range, improved clarity, and lower noise levels.

The OPPO Find X9 Ultra features some powerful video tools that are helpful for movie-makers and content creators. The device can capture videos at 8K/30fps and 4K/120fps speeds using all of its cameras. The company also includes features such as O-Log2 and ACES support for pro editing software, as well as a dedicated LUT.

Furthermore, OPPO is focusing on battery life and thermal management with the Find X9 Ultra. The mobile has a 7050mAh battery and an advanced cooling system designed to meet the rigorous demands of creative tasks.

India Launch Date and Expected Availability

OPPO will officially launch the Find X9S and Find X9 Ultra in India on May 21. The company is expected to reveal pricing and sale details during the event itself. The launch further shows OPPO’s strategy to expand its premium flagship portfolio in the Indian smartphone market.

#OPPO #Confirms #Find #X9s #Find #Ultra #India #Launch #DateOppo
How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine">Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says

How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says.

It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible.

NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a $12 billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.”

I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop).

Your Doctor Is Most Likely Consulting This Free AI Chatbot, Report Says
                How would you like it if, when stumped or just in need of some help with an unfamiliar situation, your doctor consulted a free, ad-supported AI chatbot? That’s not actually a hypothetical. They probably are doing that, a new report from NBC News says. It’s called OpenEvidence, and NBC says it was “used by about 65% of U.S. doctors across almost 27 million clinical encounters in April alone.” An earlier Bloomberg report on OpenEvidence from seven months ago said it had signed up 50% of American doctors at the time—so reported growth is rapid.

 The OpenEvidence homepage trumpets the bot as “America’s Official Medical Knowledge Platform,” and says healthcare professionals qualify for unlimited free use, but non-doctors can try it for free without creating accounts. It gives long, detailed answers with extensive citations that superficially look—to me, a non-doctor—trustworthy and credible. NBC interviewed doctors for its story, and apparently pressed them on how often they actually click those links to the sources of information, and “most said they only do so when they get an unexpected result,” NBC’s report says.

 While it’s free, OpenEvidence is not a charity. It’s a Miami-headquartered tech unicorn with a billionaire founder named David Nadler, and as of January it boasted a  billion valuation. NBC says it’s backed by some of the all stars of Sand Hill Road: Sequoia Capital and Andreessen Horowitz, along with Google Ventures, Thrive Capital, and Nvidia.

 And its revenue comes from ads (for now), which NBC says are often for “pharmaceutical and medical device companies.” I’m not capable of stress testing such a piece of software, but I kicked the tires slightly by asking Claude to generate doctor’s notes that are very bad and irresponsible (I said it was just a movie prop). ©OpenEvidence When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

  “This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”  So that’s somewhat comforting. On the other hand, according to NBC:  “[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”  NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:  “One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise. ‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”  At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?      #Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine
©OpenEvidence

When I told OpenEvidence those were my notes and asked it to make sure they were good, thankfully, it confirmed that they were bad, saying in part:

“This clinical documentation raises serious patient safety concerns. The presentation described contains multiple red flags for subarachnoid hemorrhage (SAH) that appear to have been insufficiently weighted, and the current management plan could result in significant harm.”

So that’s somewhat comforting.

On the other hand, according to NBC:

“[…]some healthcare providers were quick to point out that OpenEvidence occasionally flubbed or exaggerated its answers, particularly on rare conditions or in ‘edge’ cases.”

NBC’s report also clocked some worries within the medical community and elsewhere, in particular, a “lack of rigorous scientific studies on the tool’s patient impact,” and signs that OpenEvidence might be stunting the intellectual development of recent med school grads:

“One midcareer doctor in Missouri, who requested anonymity given the limited number of providers in their medical field in the country, said he was already seeing the detrimental effects of OpenEvidence on students’ ability to sort signals from noise.

‘My worry is that when we introduce a new tool, any kind of tool that is doing part of your skills that you had trained up for a while beforehand, you start losing those skills pretty quickly”

At a recent doctor’s appointment, my doctor asked my permission to use an AI tool on their phone (I don’t know if it was OpenEvidence). I didn’t know what to say other than yes. Do I want that for my doctor’s appointment? Not especially. But if my doctor has come to rely on a tool like this, then what am I supposed to do? Take away their crutch?

#Doctor #Consulting #Free #Chatbot #ReportArtificial intelligence,doctors,Medicine

Post Comment